← All trials
NCT04621617
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2020
- Primary completion
- Dec 31, 2021
- Completion date
- Apr 30, 2022
- First posted
- Nov 9, 2020
- Last posted
- Nov 9, 2020
- Enrollment
- 114
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Postgraduate Institute of Medical Education and ResearchLead sponsor
- Postgraduate Institute of Medical Education and ResearchOverall official - principal investigator
- Postgraduate Institute of Medical Education and ResearchReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.